Literature DB >> 17296901

Genotype-phenotype correlation in von Hippel-Lindau disease with retinal angiomatosis.

Wai T Wong1, Elvira Agrón, Hanna R Coleman, George F Reed, Karl Csaky, James Peterson, Gladys Glenn, W Marston Linehan, Paul Albert, Emily Y Chew.   

Abstract

OBJECTIVES: To characterize the germline mutations found in a large population of persons having von Hippel-Lindau (VHL) disease mutations with the clinical characteristics of associated retinal capillary hemangioblastomas (RCHs), to measure the prevalence of RCHs among patients with VHL disease generally and specifically for each genotype category, to establish genotype-phenotype correlations between genotype category and phenotypic features of ocular VHL disease, and to establish genotype-phenotype correlations between genotype category and visual function.
METHODS: Cross-sectional and molecular genetic study. Of 890 patients with VHL disease, 335 had ocular involvement in the form of RCHs. Statistical analysis was used to correlate the structure of the mutated VHL protein with the ocular phenotype.
RESULTS: Three genotype categories (amino acid substitutions, protein-truncating mutations, and complete deletions of VHL protein) were defined in all patients. The prevalence of RCHs was lowest (14.5%) among patients with complete deletions; the overall prevalence of retinal angiomatosis was 37.2%. Genotype category had no correlation with the unilaterality or bilaterality of ocular disease or with the number or extent of peripheral RCHs. The prevalence of RCHs at the juxtapapillary location was lower among patients with protein-truncating mutations compared with those with amino acid substitutions. Complete deletions were associated with the highest mean visual acuity compared with the other 2 genotype categories.
CONCLUSION: Patients with complete deletions of VHL protein have the lowest prevalence of ocular disease and the most favorable visual outcome. CLINICAL RELEVANCE: The VHL mutation genotype may be used to predict the prevalence and outcome of ocular VHL disease and to guide ophthalmic follow-up.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17296901      PMCID: PMC3019103          DOI: 10.1001/archopht.125.2.239

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  22 in total

1.  Juxtapapillary capillary hemangiomas. Clinical features and visual acuity outcomes.

Authors:  C M McCabe; H W Flynn; C L Shields; J A Shields; C D Regillo; H R McDonald; M H Berrocal; J D Gass; W F Mieler
Journal:  Ophthalmology       Date:  2000-12       Impact factor: 12.079

2.  Multiple outputation: inference for complex clustered data by averaging analyses from independent data.

Authors:  Dean Follmann; Michael Proschan; Eric Leifer
Journal:  Biometrics       Date:  2003-06       Impact factor: 2.571

Review 3.  The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis.

Authors:  Robert E Barry; Wilhelm Krek
Journal:  Trends Mol Med       Date:  2004-09       Impact factor: 11.951

4.  Fifteen year review of treated cases of retinal angiomatosis.

Authors:  W H Annesley; B C Leonard; J A Shields; W S Tasman
Journal:  Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol       Date:  1977 May-Jun

Review 5.  von Hippel-Lindau disease.

Authors:  A D Singh; C L Shields; J A Shields
Journal:  Surv Ophthalmol       Date:  2001 Sep-Oct       Impact factor: 6.048

6.  Identification of the von Hippel-Lindau disease tumor suppressor gene.

Authors:  F Latif; K Tory; J Gnarra; M Yao; F M Duh; M L Orcutt; T Stackhouse; I Kuzmin; W Modi; L Geil
Journal:  Science       Date:  1993-05-28       Impact factor: 47.728

7.  Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study.

Authors:  Hélène Dollfus; Pascale Massin; Pierre Taupin; Catherine Nemeth; Sandrine Amara; Sophie Giraud; Christophe Béroud; Pascal Dureau; Alain Gaudric; Paul Landais; Stéphane Richard
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-09       Impact factor: 4.799

8.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

Review 9.  von Hippel-Lindau disease.

Authors:  Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

Review 10.  von Hippel-Lindau disease affecting 43 members of a single kindred.

Authors:  J M Lamiell; F G Salazar; Y E Hsia
Journal:  Medicine (Baltimore)       Date:  1989-01       Impact factor: 1.889

View more
  19 in total

Review 1.  The metabolic basis of kidney cancer.

Authors:  W Marston Linehan; Christopher J Ricketts
Journal:  Semin Cancer Biol       Date:  2012-06-13       Impact factor: 15.707

2.  Genotype-phenotype correlation in ocular von Hippel-Lindau (VHL) disease: the effect of missense mutation position on ocular VHL phenotype.

Authors:  Pradeep Mettu; Elvira Agrón; Sonia Samtani; Emily Y Chew; Wai T Wong
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-07       Impact factor: 4.799

Review 3.  Von Hippel-Lindau disease (VHL): a need for a murine model with retinal hemangioblastoma.

Authors:  Stanley Park; Chi-Chao Chan
Journal:  Histol Histopathol       Date:  2012-08       Impact factor: 2.303

4.  Genotype-phenotype analysis of von Hippel-Lindau syndrome in fifteen Indian families.

Authors:  Narendranath Vikkath; Sindhu Valiyaveedan; Sheela Nampoothiri; Natasha Radhakrishnan; Gopal S Pillai; Vasantha Nair; Ginil Kumar Pooleri; Georgie Mathew; Krishnakumar N Menon; Prasanth S Ariyannur; Ashok B Pillai
Journal:  Fam Cancer       Date:  2015-12       Impact factor: 2.375

5.  Deletions at the SOX10 gene locus cause Waardenburg syndrome types 2 and 4.

Authors:  Nadege Bondurand; Florence Dastot-Le Moal; Laure Stanchina; Nathalie Collot; Viviane Baral; Sandrine Marlin; Tania Attie-Bitach; Irina Giurgea; Laurent Skopinski; William Reardon; Annick Toutain; Pierre Sarda; Anis Echaieb; Marilyn Lackmy-Port-Lis; Renaud Touraine; Jeanne Amiel; Michel Goossens; Veronique Pingault
Journal:  Am J Hum Genet       Date:  2007-10-22       Impact factor: 11.025

6.  Longitudinal analysis of retinal hemangioblastomatosis and visual function in ocular von Hippel-Lindau disease.

Authors:  Brian C Toy; Elvira Agrón; Divya Nigam; Emily Y Chew; Wai T Wong
Journal:  Ophthalmology       Date:  2012-08-17       Impact factor: 12.079

7.  Intravitreal ranibizumab therapy for retinal capillary hemangioblastoma related to von Hippel-Lindau disease.

Authors:  Wai T Wong; Katharine J Liang; Keri Hammel; Hanna R Coleman; Emily Y Chew
Journal:  Ophthalmology       Date:  2008-09-11       Impact factor: 12.079

Review 8.  Hereditary kidney cancer: unique opportunity for disease-based therapy.

Authors:  W Marston Linehan; Peter A Pinto; Gennady Bratslavsky; Elizabeth Pfaffenroth; Maria Merino; Cathy D Vocke; Jorge R Toro; Donald Bottaro; Len Neckers; Laura S Schmidt; Ramaprasad Srinivasan
Journal:  Cancer       Date:  2009-05-15       Impact factor: 6.860

9.  Retinal vascular proliferation as an ocular manifestation of von Hippel-Lindau disease.

Authors:  Wai T Wong; Steven Yeh; Chi-Chao Chan; Robert E Kalina; James L Kinyoun; James C Folk; Hanna R Coleman; Emily Y Chew
Journal:  Arch Ophthalmol       Date:  2008-05

Review 10.  Ocular von Hippel-Lindau disease: clinical update and emerging treatments.

Authors:  Wai T Wong; Emily Y Chew
Journal:  Curr Opin Ophthalmol       Date:  2008-05       Impact factor: 3.761

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.